Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydronidone capsules safety in hepatic fibrosis and cirrhosis
CTR20260052Phase 3Completed
- Sponsor
- Gyre Pharmaceuticals
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of hydronidone in hepatic fibrosis, Cirrhosis and Chronic Hepatitis B (CHB), sponsored by Gyre Pharmaceuticals. Primary endpoint: Incidence and severity of adverse events. Started Mar 2026; status: completed.
02
Drugs
hydronidone
03
Conditions
hepatic fibrosisCirrhosisChronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20260052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260052.